Patents Assigned to Takeda Chemical Industry, Ltd.
-
Patent number: 6391905Abstract: A compound represented by the formula: wherein X represents a sulfur atom or an oxygen atom; Y represents an optionally oxidized sulfur atom or an oxygen atom; Z represents a bond or a divalent hydrocarbon group; R1 represents an optionally substituted hydrocarbon group; R2 represents an optionally amidated or esterified carboxyl group; ring A represents an optionally substituted aromatic 5-membered heterocyclic ring; or a salt thereof. A compound of the above formula possesses cell differentiation inducing factor action-enhancing activity and anti-matrix metalloprotease activity and that is useful in the prevention and treatment of bone diseases such as osteoporosis, bone fractures, osteoarthritis and rheumatoid arthritis, arteriosclerosis, cancer metastasis, and diseases based on nerve degeneration.Type: GrantFiled: May 3, 2001Date of Patent: May 21, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Tsuneo Yasuma, Tsuneo Oda, Masatoshi Hazama, Shigehisa Taketomi
-
Patent number: 6387687Abstract: A microorganism having indolmycin-producing ability and tryptophan analogue resistance is provided, and indolmycin or its salt can be produced efficiently by cultivating such microorganism in a medium to produce and accumulate indolmycin or its salt in the culture broth followed by recovering a product.Type: GrantFiled: January 23, 2001Date of Patent: May 14, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Akihiko Naotsuka, Motoo Izawa, Ken-ichiro Miyagawa
-
Patent number: 6384062Abstract: Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.Type: GrantFiled: October 11, 2001Date of Patent: May 7, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Hitoshi Ikeda, Takashi Sohda, Hiroyuki Odaka
-
Patent number: 6380234Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula wherein R1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R3 and R5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.Type: GrantFiled: August 8, 2001Date of Patent: April 30, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Tadashi Makino, Tetsuro Tabata, Shin-Ichiro Hirai
-
Patent number: 6376536Abstract: This invention is to provide a compound for antagonizing CCR5, said compound being represented by the formula: wherein R1 is an optionally substituted phenyl or an optionally substituted thienyl; Y is —CH2—, —S— or —O—; and R2, R3 and R4 are independently an optionally substituted aliphatic hydrocarbon group or an optionally substituted alicyclic heterocyclic ring group, and being effective for the prevention and treatment of infectious disease of HIV.Type: GrantFiled: May 26, 2000Date of Patent: April 23, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Mitsuru Shiraishi, Masanori Baba, Yoshio Aramaki, Osamu Nishimura, Naoyuki Kanzaki
-
Patent number: 6376461Abstract: According to a first embodiment, there is provided a sustained-release preparation comprising a water-insoluble or slightly water-soluble polyvalent metal salt of a water-soluble physiologically active substance which is not an endothelin antagonist, and a biodegradable polymer. The sustained-release preparation of the first embodiment is highly efficient in incorporating the water-soluble physiologically active substance and suppresses the initial burst of the water-soluble physiologically active substance. The sustained-release preparation of the present invention is capable of releasing the water-soluble physiologically active substance while retaining its bioactivity after administration in vivo. Furthermore, the water-soluble physiologically active substance in the sustained-release preparation is kept stable for a long period of time, with little loss of bioactivity.Type: GrantFiled: October 26, 1999Date of Patent: April 23, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Yasutaka Igari, Yutaka Yamagata, Satoshi Iinuma, Hiroaki Okada, Kazumichi Yamamoto
-
Patent number: 6371941Abstract: A prefilled syringe has a tubular body which has an open front end and an open rear end. A front assembly is mounted on an outer periphery of a front end portion of the tubular body. A finger grip is mounted on an outer periphery of a rear end portion of the tubular body. A front sealing member is provided in the tubular body so as to be disposed forwardly of injection liquid and a rear sealing member is provided in the tubular body so as to be disposed rearwards of the injection liquid. A plunger rod is provided so as to be movable in the tubular body. A temporary stop member temporarily stops the plunger rod through retention of the temporary stop member by the finger grip such that the rear sealing member is temporarily stopped at a predetermined position of the tubular body. A retention canceling member cancels the retention of the temporary stop member by the finger grip without moving the plunger rod.Type: GrantFiled: September 10, 1998Date of Patent: April 16, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Masahiko Kato, Jiichi Arai, Makoto Kakiuti
-
Patent number: 6368635Abstract: A solid matrix composition which is solid at ambient temperature, which comprises a viscogenic agent, such as an acrylic acid polymer, capable of developing viscosity on contact with water, as dispersed at least in the neighborhood of the surface layer of a matrix particle containing a polyglycerol fatty acid ester or a lipid and an active ingredient. The matrix may be such that a matrix particle containing a polyglycerol fatty acid ester or a lipid and an active ingredient has been coated with a coating composition containing at least one viscogenic agent. Such composition can adhere to the digestive tract and remain there for a prolonged period of time, thereby increasing the bioavailability of the active ingredient. Solid preparations, such as fine granules and granules, contain the above matrix composition.Type: GrantFiled: December 18, 1997Date of Patent: April 9, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Yohko Akiyama, Naoki Nagahara, Shin-ichiro Hirai
-
Publication number: 20020039598Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula 1Type: ApplicationFiled: August 8, 2001Publication date: April 4, 2002Applicant: Takeda Chemical Industries, Ltd.Inventors: Tadashi Makino, Tetsuro Tabata, Shin-Ichiro Hirai
-
Patent number: 6365725Abstract: Disclosed are (1) a DNA containing a cDNA segment coding for human endothelin-2 (SEQ ID NO:1), (2) a precursor of human endothelin-2 (SEQ ID NO:2), (3) a transformant carrying a DNA containing a cDNA segment coding for human endothelin-2, and (4) a method for preparing mature human endothelin-2 which comprises culturing the transformant described in (3), accumulating a protein in a culture medium, and collecting the same, whereby human endothelin-2 and the precursors thereof can be produced in large amounts.Type: GrantFiled: July 10, 1991Date of Patent: April 2, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Haruo Onda, Shoichi Ohkubo
-
Patent number: 6365607Abstract: A medicinal composition for the prophylaxis and treatment of cachexia which comprises a compound of the formula: wherein R represents a hydrocarbon group that may be substituted or a heterocyclic group that may be substituted; Y represents a group of the formula —CO—, —CH(OH)—, or —NR3— (R3 represents an alkyl group that may be substituted); m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a bond or a bivalent aliphatic hydrocarbon group having 1 to 7 carbon atoms; Q represents oxygen or sulfur; R1 represents hydrogen or an alkyl group; ring E may have further 1 to 4 substituents, which may form a ring in combination with R1; L and M respectively represent hydrogen or may be combined with each other to form a bond, provided that when m and n are 0, X represents CH, A represents a bond, Q represents sulfur, R1, L and M respectively represent hydrogen, and ring E does not have further substituents, R does not represent dihydrobenzopyranyl; orType: GrantFiled: June 28, 2000Date of Patent: April 2, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Yu Momose, Etsuya Matsutani, Takashi Sohda
-
Patent number: 6362206Abstract: The present invention provides an azole compound represented by the formula (I): wherein Ar is an optionally substituted phenyl group; R1 and R2, the same or different, are a hydrogen atom or a lower alkyl group, or R1 and R2 may combine together to form a lower alkylene group; R is a hydrogen atom or an acyl group; X is a nitrogen atom or a methine group; A is Y═Z (Y and Z, the same or different, are a nitrogen atom or a methine group optionally substituted with a lower alkyl group) or an ethylene group optionally substituted with a lower alkyl group; n is an integer from 0 to 2; and Az is an optionally substituted azolyl group, or its salt, which is useful for a prevention and therapy of a fungal infection of a mammal as a antifungal agent.Type: GrantFiled: October 7, 1999Date of Patent: March 26, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Katsumi Itoh, Kenji Okonogi, Akihiro Tasaka
-
Patent number: 6359134Abstract: The present invention provides compounds which specifically inhibit FXa, which are effective when orally administered and which are useful as a safe medicine for the prevention or treatment of diseases caused by thrombus or infarction.Type: GrantFiled: November 30, 1999Date of Patent: March 19, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Hiroyuki Tawada, Fumio Ito, Norihiko Moriya, Zen-ichi Terashita
-
Patent number: 6355672Abstract: The invention provides compounds of the formula: wherein the ring A is an optionally substituted benzene ring; R1 is an optionally substituted non-aromatic heterocyclic group; R2 and R3 are independently hydrogen atom or an optionally substituted hydrocarbon group; n is an integer of 0-3; or salts thereof, which are useful as medicines having an osteogenesis promoting effect and chondrogensis promoting effect. The present invention relates to an amine compound having an excellent effect of inhibiting production and/or secretion of amyloid-b protein, a production and use thereof. Especially, it is effective for preventing and/or treating, for example, neurodegenerative diseases, amyloid angiopathy, neurological disorders caused by cerebrovascular disorders, and so forth.Type: GrantFiled: January 30, 2001Date of Patent: March 12, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Tsuneo Yasuma, Haruhiko Makino, Akira Mori
-
Patent number: 6355808Abstract: Benzimidazole derivatives of the formula (I): wherein the ring A is a benzene ring which may optionally contain substitution in addition to the R′ group; R1 is hydrogen or an optionally substituted hydrocarbon residue; R2 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; R′ is carboxyl, an ester thereof, an amide thereof or a group capable of forming an anion or convertible to an anion; Y is —O—, —S(O)m— or —N(R4)— wherein m is an integer of 0, 1 or 2 and R4 is hydrogen or an optionally substituted alkyl group; and n is an integer of 1 or 2; and the pharmaceutically acceptable salts thereof, have potent angiotensin Π antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g.Type: GrantFiled: March 27, 2001Date of Patent: March 12, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Takehiko Naka, Kohei Nishikawa, Takeshi Kato
-
Publication number: 20020028198Abstract: This invention relates to glutamine:fructose-6-phosphate amidotransferase, or its partial peptide or a salt thereof; a DNA coding for the protein; a recombinant vector; a transformant; a method for producing the protein; a pharmaceutical composition comprising the protein, its partial peptide or a salt thereof; and an antibody against the protein or its partial peptide. The protein, its partial peptide or a salt thereof, and the DNA are useful for a prophylactic or therapeutic agent for hypoglycemia. The antibody can be used in the assay of the protein, its partial peptide or a salt thereof. The protein, its partial peptide or a salt thereof is useful as a reagent for the screening for candidate medical compounds.Type: ApplicationFiled: January 29, 2001Publication date: March 7, 2002Applicant: Takeda Chemical Industries, Ltd.Inventors: Kazunori Nishi, Yukiko Hikichi, Yasushi Shintani
-
Patent number: 6352982Abstract: The present invention provides a compound of the formula: wherein ring A is an optionally substituted aromatic hydrocarbon ring or aromatic heterocyclic ring; ring B is an optionally substituted aromatic hydrocarbon ring or aromatic heterocyclic ring; Z is an optionally substituted cyclic group or linear hydrocarbon group; R1 is a hydrogen atom, an optionally substituted hydrocarbon group or heterocyclic ring; R2 is an optionally substituted amino group; D is a bond or an optionally substituted divalent hydrocarbon group; E is a bond, —CON(Ra)—, —N(Ra)CO—, —N(Rb)CON(Rc)—, —N(Rd)COO—, —N(Re)SO2—, —COO—, —N(Rf)—, —O—, —S— —SO—, —SO2—, (in which Ra, Rb, Rc, Rd, Re and Rf are respectively a hydrogen atom or an optionally substituted hydrocarbon group); G is a bond or an optionally divalent substituted hydrocarbon group; L is a divalent group; ringType: GrantFiled: October 14, 1999Date of Patent: March 5, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Hiroshi Mabuchi, Nobuhiro Suzuki, Takashi Miki
-
Patent number: 6352775Abstract: The anisotropic conductive adhesives containing the conductive, multilayer-structured resin particles in which at least one inner layer is more flexible than the outermost layer and is chemically bound to at least one of the two adjacent layers and the surface of the outermost layer is covered with a metal make connections at lowered pressure enough to suppress development of cracking of the ITO electrode and also can provide enhanced stability, especially stability of connection over a prolonged period of time.Type: GrantFiled: August 1, 2000Date of Patent: March 5, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Ichiro Sasaki, Tatsuo Fujii, Shinji Tachibana
-
Patent number: 6350749Abstract: The present invention is to provide a compound of the formula: wherein the ring A is an optionally substituted 5- to 6-membered aromatic heterocyclic ring, the ring B an optionally substituted 5- to 6-membered aromatic homocyclic ring or an optionally substituted 5- to 6-membered aromatic heterocyclic ring, R1 is a hydrogen atom, a hydroxy group or a lower alkyl group, and n is 0 or 1, or a salt thereof, which is effective for the prevention or treatment of ischemic cardiac disease, etc., and which is useful as an agent for preventing or treating ischemic cardiac disease, etc. such as myocardial infarction, arrhythmia, etc.Type: GrantFiled: August 8, 2000Date of Patent: February 26, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Mitsuru Shiraishi, Shoji Fukumoto, Keiji Kusumoto
-
Patent number: 6348481Abstract: This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula wherein R1 is H or an optionally substituted hydrocarbon residue; R2 is an optionally esterified carboxyl group; R3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R2; and Y is a bond, —O—, —S(O)m— (wherein m is 0, 1 or 2) or —N(R4)— (wherein R4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.Type: GrantFiled: January 12, 2001Date of Patent: February 19, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Yoshiyuki Inada, Keiji Kubo